EUVIMEDEUVIMED entdecken
Open Access

Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease

Nigel Bourne, Celeste A Keith, Aaron L Miller, Richard B Pyles, Gary Cohen, Gregg N Milligan iD

Journal of Virology · 2023

DOI: 10.1128/jvi.00669-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2023. Verfasst von Nigel Bourne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas, USA. Hauptthemen laut MEDLINE: Herpes Genitalis, Herpes Simplex, Herpesvirus 2, Human. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Boosting herpes simplex virus (HSV)-specific immunity in the genital tissues of HSV-positive individuals to increase control of HSV-2 recurrent disease and virus shedding is an important goal of therapeutic immunization and would impact HSV-2 transmission. Experimental therapeutic HSV-2 vaccines delivered by a parenteral route have resulted in decreased recurrent disease in experimental animals. We used a guinea pig model of HSV-2 infection to test if HSV-specific antibody and cell-mediated responses in the vaginal mucosa would be more effectively increased by intravaginal (Ivag) therapeutic immunization compared to parenteral immunization. Therapeutic immunization with HSV glycoproteins and CpG adjuvant increased glycoprotein-specific IgG titers in vaginal secretions and serum to comparable levels in Ivag- and intramuscular (IM)-immunized animals. However, the mean numbers of HSV glycoprotein-specific antibody secreting cells (ASCs) and IFN-γ SCs were greater in Ivag-immunized animals demonstrating superior boosting of immunity in the vaginal mucosa compared to parenteral immunization. Therapeutic Ivag immunization also resulted in a significant decrease in the cumulative mean lesion days compared to IM immunization. There was no difference in the incidence or magnitude of HSV-2 shedding in either therapeutic immunization group compared to control-treated animals. Collectively, these data demonstrated that Ivag therapeutic immunization was superior compared to parenteral immunization to boost HSV-2 antigen-specific ASC and IFN-γ SC responses in the vagina and control recurrent HSV-2 disease. These results suggest that novel antigen delivery methods providing controlled release of optimized antigen/adjuvant combinations in the vaginal mucosa would be an effective approach for therapeutic HSV vaccines. IMPORTANCE HSV-2 replicates in skin cells before it infects sensory nerve cells where it establishes a lifelong but mostly silent infection. HSV-2 occasionally reactivates, producing new virus which is released back at the skin surface and may be transmitted to new individuals. Some HSV-specific immune cells reside at the skin site of the HSV-2 infection that can quickly activate and clear new virus. Immunizing people already infected with HSV-2 to boost their skin-resident immune cells and rapidly control the new HSV-2 infection is logical, but we do not know the best way to administer the vaccine to achieve this goal. In this study, a therapeutic vaccine given intravaginally resulted in significantly better protection against HSV-2 disease than immunization with the same vaccine by a conventional route. Immunization by the intravaginal route resulted in greater stimulation of vaginal-resident, virus-specific cells that produced antibody and produced immune molecules to rapidly clear virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes GenitalisHerpes SimplexHerpesvirus 2, HumanAnimalsFemaleGuinea PigsHumansAdjuvants, ImmunologicAntibodies, ViralGlycoproteinsHerpesvirus 1, CercopithecineImmunizationT-LymphocytesVagina

Stichwörter der Autor:innen

HSV-2guinea pigrecurrent HSV-2 diseasetherapeutic vaccinevaginal mucosa

Substanzen

Adjuvants, ImmunologicAntibodies, ViralGlycoproteins

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas, USA.
  • Department of Pediatrics, University of Texas Medical Branch , Galveston, Texas, USA.
  • Sealy Institute for Vaccine Sciences, University of Texas Medical Branch , Galveston, Texas, USA.
  • Department of Basic and Translational Sciences, University of Pennsylvania , Philadelphia, Pennsylvania, USA.

ORCID-Profile: Gregg N Milligan

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Bourne, N., Keith, C. A., Miller, A. L., Pyles, R. B., Cohen, G., & Milligan, G. N. (2023). Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease. Journal of Virology. https://doi.org/10.1128/jvi.00669-23

Vancouver

Bourne N, Keith CA, Miller AL, Pyles RB, Cohen G, Milligan GN. Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease. Journal of Virology. 2023. doi:10.1128/jvi.00669-23

BibTeX
@article{Bourne2023,
  author = {Bourne, Nigel and Keith, Celeste A and Miller, Aaron L and Pyles, Richard B and Cohen, Gary and Milligan, Gregg N},
  title = {Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease},
  journal = {Journal of Virology},
  year = {2023},
  doi = {10.1128/jvi.00669-23}
}
Kostenlos starten →